Cytomx analysts
WebMar 27, 2024 · CytomX Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2024, missing the Zacks Consensus... WebWhat are analysts forecasts for CytomX stock? The 16 analysts offering price forecasts for CytomX have a median target of 6.42, with a high estimate of 16.00 and a low estimate …
Cytomx analysts
Did you know?
WebJan 6, 2024 · January 6, 2024, 1:46 PM · 3 min read Shares of CytomX Therapeutics CTMX were up 55.3% in after-market trading on Jan 5 after management announced its collaboration agreement with Moderna … WebApr 14, 2024 · Analysts at StockNews.com initiated coverage on shares of DAVIDsTEA ( NASDAQ:DTEA – Get Rating) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating...
WebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Rating) has received an average rating of "Hold" from the twelve analysts that are covering the firm, Marketbeat reports.One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and two have assigned a buy recommendation to the … WebOct 8, 2015 · Based in South San Francisco, CA, CytomX Therapeutics (NASDAQ: CTMX) scheduled a $97 million IPO on Nasdaq with a market capitalization of $524 million at a price range midpoint of $15 for ...
WebDXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security … WebApr 9, 2024 · 8 Analysts CTMX Stock Overview CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. About the company Risk Analysis Negative shareholders equity Currently unprofitable and not forecast to become profitable over the next 3 years See All Risk Checks My Notes
WebMar 30, 2024 · CytomX Therapeutics Stock Performance NASDAQ:CTMX opened at $1.54 on Thursday. The firm's fifty day simple moving average is $2.25 and its 200 day simple moving average is $1.84. CytomX Therapeutics has a twelve month low of $1.17 and a twelve month high of $3.02. Institutional Investors Weigh In On CytomX Therapeutics
WebApr 6, 2024 · According to analysts, CytomX Therapeutics's stock has a predicted upside of 87.89% based on their 12-month price targets. What analysts cover CytomX … santa clara valley groundwater basinWebApr 14, 2024 · The consensus estimate for Apple’s current full-year earnings is $6.05 per share. KeyCorp also issued estimates for Apple’s Q3 2024 earnings at $1.11 EPS, Q4 2024 earnings at $1.48 EPS, FY2024 ... short nylon nightgowns vanity fairWebApr 6, 2024 · Find the latest CytomX Therapeutics, Inc. (CTMX) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. … short nylon nightie croppedWebThe latest price target for CytomX Therapeutics ( NASDAQ: CTMX) was reported by Mizuho on Tuesday, March 28, 2024. The analyst firm set a price target for 2.00 expecting CTMX to rise to within 12 ... short nylon nightgownsWebApr 6, 2024 · CytomX Therapeutics is a smaller company with a market capitalization of US$181m, so it may still be flying under the radar of many institutional investors. In the chart below, we can see that... santa clara veterans disability lawyer vimeoWebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) has received an average rating of “Hold” from the twelve analysts that are covering the firm, Marketbeat … short nylon shortsWebCytomX Therapeutics, Inc. Analyst Report: AbbVie Inc AbbVie, a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. … short nylon socks